Perrigo Company (NYSE:PRGO)‘s stock had its “buy” rating restated by UBS AG in a report issued on Thursday, 99wallstreet.com reports. They currently have a $98.00 price target on the stock, up from their prior price target of $84.00. UBS AG’s target price points to a potential upside of 12.35% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Royal Bank Of Canada set a $60.00 target price on shares of Perrigo and gave the stock a “sell” rating in a report on Sunday, July 16th. Jefferies Group LLC restated a “hold” rating and set a $71.00 price target (up previously from $69.00) on shares of Perrigo in a research report on Friday, August 11th. Wells Fargo & Company restated a “market perform” rating and set a $77.00 price target on shares of Perrigo in a research report on Tuesday, August 15th. Oppenheimer Holdings, Inc. assumed coverage on shares of Perrigo in a research report on Thursday, September 7th. They set an “outperform” rating and a $88.00 price target for the company. Finally, BidaskClub upgraded shares of Perrigo from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 9th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $88.50.

Perrigo (PRGO) traded down 0.52% on Thursday, hitting $86.78. 129,091 shares of the company were exchanged. The stock’s market cap is $12.38 billion. The firm has a 50 day moving average of $82.62 and a 200-day moving average of $74.62. Perrigo has a 52-week low of $63.68 and a 52-week high of $94.95.

Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, August 10th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.28. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.18 billion. Perrigo had a negative net margin of 51.04% and a positive return on equity of 11.55%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.93 earnings per share. On average, equities analysts expect that Perrigo will post $4.58 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/05/perrigos-prgo-buy-rating-reiterated-at-ubs-ag.html.

In other news, EVP Jeffrey Needham sold 3,595 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $89.49, for a total transaction of $321,716.55. Following the completion of the transaction, the executive vice president now owns 10,118 shares in the company, valued at approximately $905,459.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Thomas Farrington sold 616 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $76.90, for a total transaction of $47,370.40. Following the transaction, the executive vice president now owns 2,724 shares of the company’s stock, valued at approximately $209,475.60. The disclosure for this sale can be found here. Insiders sold a total of 6,894 shares of company stock valued at $581,320 in the last quarter. 6.90% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the company. Korea Investment CORP boosted its position in shares of Perrigo by 142.0% during the 2nd quarter. Korea Investment CORP now owns 1,331 shares of the company’s stock valued at $101,000 after purchasing an additional 781 shares in the last quarter. Commonwealth Bank of Australia boosted its position in shares of Perrigo by 13.8% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,455 shares of the company’s stock valued at $108,000 after purchasing an additional 176 shares in the last quarter. Johnson Financial Group Inc. boosted its position in shares of Perrigo by 15.6% during the 1st quarter. Johnson Financial Group Inc. now owns 1,775 shares of the company’s stock valued at $118,000 after purchasing an additional 240 shares in the last quarter. Global X Management Co. LLC boosted its position in shares of Perrigo by 56.4% during the 1st quarter. Global X Management Co. LLC now owns 2,370 shares of the company’s stock valued at $157,000 after purchasing an additional 855 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in shares of Perrigo by 1,046.2% during the 2nd quarter. Bessemer Group Inc. now owns 2,235 shares of the company’s stock valued at $169,000 after purchasing an additional 2,040 shares in the last quarter. Institutional investors own 82.44% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.